Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

Bringing migration research under one roof.

Funded by Led by

This project was made possible thanks to funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement Ares(2017) 5627812-77012.